TY  - JOUR
AU  - Mendez-Vidal, Maria Jose
AU  - Molina, Aurea
AU  - Anido, Urbano
AU  - Chirivella, Isabel
AU  - Etxaniz, Olatz
AU  - Fernandez-Parra, Eva
AU  - Guix, Marta
AU  - Hernandez, Carolina
AU  - Lambea, Julio
AU  - Montesa, Alvaro
AU  - Pinto, Alvaro
AU  - Ros, Silverio
AU  - Gallardo, Enrique
PY  - 2018
DO  - 10.1186/s40360-018-0264-8
UR  - http://hdl.handle.net/10668/13239
T2  - BMC pharmacology & toxicology
AB  - Pazopanib is indicated in the first-line treatment of metastatic renal cell cancer (mRCC). The aim of this study was to review the efficacy, safety, and pharmacokinetics of pazopanib and see how these aspects are linked to clinical practice. A...
LA  - en
PB  - BioMed Central
KW  - Antineoplastic agents
KW  - Carcinoma, renal cell
KW  - Kidney neoplasms
KW  - Pazopanib
KW  - Protein kinase inhibitors
KW  - Quality of life
KW  - Área de Gestión Sanitaria Sur de Sevilla
KW  - Angiogenesis Inhibitors
KW  - Carcinoma, Renal Cell
KW  - Humans
KW  - Indazoles
KW  - Kidney Neoplasms
KW  - Pyrimidines
KW  - Quality of Life
KW  - Sulfonamides
KW  - Treatment Outcome
TI  - Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma.
TY  - research article
VL  - 19
ER  -